RT @ucl_discovery: Open Access UCL Research: Prognostic value of test(s) for O6-methylguanine-DNA methyltransferase (MGMT) promoter methyla…
Open Access UCL Research: Prognostic value of test(s) for O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation for predicting overall survival in people with glioblastoma treated with temozolomide https://t.co/I6LlPwg8DC
RT @Franspi: And super ⭐️⭐️ sys reviewers @A_McAleenan and @Claire_J_Kelly !! https://t.co/0nuov51btI
And super ⭐️⭐️ sys reviewers @A_McAleenan and @Claire_J_Kelly !!
RT @BrisCancerEpi: New @CochraneLibrary from ICEP's Kathreena Kurian, @Franspi and collaborators: systematic review of standards for assess…
RT @BrisCancerEpi: New @CochraneLibrary from ICEP's Kathreena Kurian, @Franspi and collaborators: systematic review of standards for assess…
New @CochraneLibrary from ICEP's Kathreena Kurian, @Franspi and collaborators: systematic review of standards for assessing MGMT biomarker, used worldwide in brain tumour glioblastoma for prognosis and treatment stratification. https://t.co/BQHjb45ksw
RT @Franspi: 2/2 our systematic review on the prognostic value of test(s) for MGMT promoter methylation for predicting overall survival in…
2/2 our systematic review on the prognostic value of test(s) for MGMT promoter methylation for predicting overall survival in people with glioblastoma treated with TMZ is part of this collection @A_McAleenan @BrisCancerEpi https://t.co/ODxrtPeVBY
Prognostic value of test(s) for O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation for predicting overall survival in people with glioblastoma treated with temozolomide Led by @MedicalBristol 👉https://t.co/CeM292hI4T